Alcon Inc. Ordinary Shares (NY:ALC)

69.93 -0.06 (-0.09%)

Delayed Quote Updated: 10:46 AM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alcon Inc. Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet

February 24, 2025

From Alcon Inc. Investors

Via Business Wire

Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension

February 19, 2025

From Alcon Inc. Investors

Via Business Wire

Apple To $253? Here Are 10 Top Analyst Forecasts For Friday ↗

January 24, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Alcon Analysts Increase Their Forecasts After Q2 Results ↗

August 22, 2024

Via Benzinga

Alcon Analysts Increase Their Forecasts Following Q1 Results ↗

May 15, 2024

Via Benzinga

Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference

December 31, 2024

From Alcon Inc. Investors

Via Business Wire

Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

December 17, 2024

Via Benzinga

Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation

November 12, 2024

From Alcon Inc. Investors

Via Business Wire

Alcon Debuts Groundbreaking PRECISION7, a One-Week Replacement Contact Lens to Start and End Every Week Fresh

November 07, 2024

From Alcon Inc. Investors

Via Business Wire

Alcon Innovations on Display at AAO 2024 Demonstrate Efficiency and Performance

October 15, 2024

From Alcon Inc. Investors

Via Business Wire

Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value

September 25, 2024

The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden.

Via MarketBeat

Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 12, 2024

Via Benzinga

ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q2 2024 ↗

August 20, 2024

ALC stock results show that Alcon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Via InvestorPlace

Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses

August 20, 2024

From Alcon Inc. Investors

Via Business Wire

S&P 500, Nasdaq Extend Gains For 8th Consecutive Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone ↗

August 20, 2024

Via Benzinga

Topics Stocks

Lowe's, Palo Alto Networks And 3 Stocks To Watch Heading Into Tuesday ↗

August 20, 2024

Via Benzinga

Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED ↗

August 17, 2024

Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to...

Via Talk Markets

US Stocks Trim Gains As Iran Mulls Attack On Israel; Gold, Oil Rally: What's Driving Markets Monday? ↗

August 12, 2024

Wall Street turns negative due to geopolitical risks. Gold rises 1.5% and stocks edge higher. Scotiabank acquires minority stake in KeyCorp.

Via Benzinga

Nasdaq, S&P 500 Futures Climb After Volatile Week As Traders Eye Inflation Data and Retail Earnings: Strategist Says Not CPI But This Data Can Give People Lot Of Conviction ↗

August 12, 2024

The resilience of the market was in full display on Monday after last week’s “historical comeback” by the market. The major index futures traded higher, albeit by a modest magnitude.

Via Benzinga

Topics Economy Stocks

Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock? ↗

July 16, 2024

Johnson & Johnson has beaten earnings per share in more than 10 straight quarters. Will the trend continue in Q2?

Via Benzinga

Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

June 24, 2024

From Alcon Inc. Investors

Via Business Wire

ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q1 2024 ↗

May 20, 2024

ALC stock results show that Alcon beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Do You Have Your Eye On Vision Care Stocks? ↗

May 20, 2024

For investors seeking stable and growing opportunities, eye care stocks are an attractive option.

Via Talk Markets

MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio? ↗

May 19, 2024

Top performing large-cap stocks in the last week: MSTR, MNDY, ONON, SE, PODD, DELL, VOD, ALC, SMCI, CRBG. Analysts raise price targets & more positive news.

Via Benzinga

Contact Lens Maker Alcon's Has New Growth Avenues, Analyst Upgrades Stock ↗

May 15, 2024

Alcon's recent upgrades and promising opportunities, including the BELKIN Vision acquisition, expanding glaucoma treatment options, enhanced PanOptix IOL, and market advancements in China.

Via Benzinga

Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 14, 2024

Via Benzinga

Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday ↗

May 14, 2024

Via Benzinga

Why Alcon Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗

May 14, 2024

Via Benzinga

2 Intriguing Medical Stocks To Buy For Steady Growth As Earnings Approach ↗

May 14, 2024

Among the medical sector, Alcon and Prestige Consumer Healthcare are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.